A feature selection (FS) 
Introduction
Chest pain is one of the most common complaints with patients arriving at Emergency Department (ED) with approximately 6 million patients presenting annually in the United States [1] . Of those admitted, only 10% to 13% have a confirmed Acute Myocardial Infarction (AMI) [2] . Challenges exist in providing early and accurate diagnosis of AMI in patients admitted to ED with chest pain of suspected cardiac origin. Additionally, many current standard diagnostic tests are not accurate enough to rule-out MI at presentation [3] or under 3 hours in ECG negative patients providing a burden to overcrowded ED. Inappropriate discharge however is associated with a 5-fold increase in mortality and morbidity [4] .
AMI is diagnosed by history, clinical examination, electrocardiogram (ECG) and measurement of cardiac biomarkers including high sensitive troponin T (hscTnT). This study aimed to explore additional biomarkers that could add more diagnostic capabilities to hs-cTnT (which is the gold standard) in the detection of AMI in patients presented to ED with chest pain of suspected cardiac origin. This retrospective analysis for feature selection takes biomarkers measured at multiple timepoints after presentation apart from the initial ECG to assist in the detection of AMI.
Methods

Recruitment of patients and data
Consecutive patients (age>18 years) with chest pain of presumed ischaemic origin were recruited at Craigavon Area and Daisy Hill hospitals in Northern Ireland between October 2009 and October 2011. Exclusion criteria comprise symptom onset >12 hours prior to recruitment, had a terminal malignancy, had received thrombolysis prior to recruitment, were receiving chronic anticoagulant therapy or had been previously recruited into the study. Time of symptom onset was determined following patient interview. The study complies with the Declaration of Helsinki and was approved both by the Office for Research Ethics Northern Ireland and the Southern Health and Social Care Trust Research and Development Department. Written informed consent was obtained from all participating patients.
A 12-lead ECG was obtained on presentation and indicators of anomalies were annotated (abnormal Q wave, ST shift and T wave inversion). Blood was drawn on presentation (time 0 hour) and at subsequent timepoints if required (1, 2, 3, 6, 12 and 24 hours) for the measurement of biomarkers hs-cTnT, Creatine Kinase-MB (CK-MB), Myoglobin, GPBB, Heart-type Fatty Acid-Binding Protein (H-FABP), CAIII, Troponin I (cTnI), Troponin T (cTnT) and NTproBNP.
Diagnosis of AMI was established according to the universal definition of MI at the time [5] . The final diagnosis was adjudicated by two independent clinicians who had all the clinical, laboratory and imaging data available.
548 cases were recruited and 70 cases of ST Elevation MI (STEMI) were not included in the analysis since those cases are treated by PCI (in hospitals where it is available) and would not routinely have biomarkers measured. Thus the number of cases was reduced from 548 to 478 including 97 Non ST Elevation MI (NSTEMI).
Feature selection
Measured biomarkers for segregating cases of MI from non-MI were analysed by the area under the receiver operator characteristic curve (AUROC) and logistic regression. Calculations were carried out using R version 3.1.0 and for AUROC analysis the package "pROC" [6] was used. Level of statistical significance was fixed at 0.05 for comparisons. Values were rounded to four decimal places. The biomarkers exhibiting the highest AUROC with no statistical significant difference were chosen as candidate markers for further exploration. Cases with missing values were excluded and no imputation of the data was carried out.
Results
AUROC
H-FABP, hs-cTnT, CK-MB, GPBB, CAIII, Myoglobin, c-TnI, NTproBNP and c-TnT were analysed using AUROC at different times from presentation.
According to table 1, hs-cTnT at presentation had the highest AUROC of all the biomarkers but was not statistically different to H-FABP (p=0.0587). The pattern of superiority for AUCROC of hs-cTnT is repeated at 3 hours (table 2) but it is not statistically different to H-FABP (p=0.1239). 
Logistic regression
Logistic regressions were used to show the predictive capabilities of combinations of biomarkers collected at different timepoints. hs-cTnT, H-FABP and CK-MB were included as predictors of AMI in two models for data collected up to 1 hour and 3 hours.
A model is presented in table 3 with data collected up to 1 hour from presentation (0 hour) that used biomarkers from 335 patients, 67 NSTEMIs and without missing values for the biomarkers involved. A corresponding label for the timepoint was added to the name of the biomarker for naming the variables. 
3.3.
Peaking times for AMI 
Comparison of algorithms
Algorithms to detect MI based on biomarkers at different thresholds were compared using the Pencina's Net Reclassification Improvement (NRI) [7] . The initial focus was towards algorithms at presentation. H-FABP and hs-cTnT are preferred over CK-MB according to the AUROC and logistic regression models. Some comparisons to the gold standard hs-cTnT>=14ng/l are shown in Table 5 . The threshold of 14ng/l is the 99th percentile widely used for AMI detection and it is used here as a reference. For instance, according to the first row in table 5, an algorithm based on H-1.5μg/l to detect MI at presentation is more sensitive than one based on hs-c l (net gain with MI of 0.0462) but less specific (negative net gain with non-MI of -0.3765), and the probability of |NRI| (absolute value of the sum of the two net gains) higher than |-0.3303| is low (p<0.00005) if the hypothesis of NRI zero is assumed. Thus it can be concluded that these two algorithms are statistically different in terms of NRI and the negative value shows no overall improvement of the algorithm. However it is not the case when comparing Hl against l (p=0.1073) (third row in table 5). The cutoff of 3.8μg/l was used to show no difference. 
Discussion
Cardiac troponin is currently the main biomarker assisting in the detection of AMI. With the dataset used (focused on NSTEMI only) the analysis demonstrated that hs-cTnT consistently had a higher AUROC than the other biomarkers but the statistical difference to H-FABP could not be stablished at presentation (p=0.0587) (table 1) and at 3 hours after presentation (p=0.1239) (table 2) .
H-FABP was also a strong predictor of AMI according to logistic regression models especially at 0 and 1hour (tables 3 and 4). In those models H-FABP was combined with hs-cTnT and CK-MB.
H-FABP, measured at presentation and acting as a sole biomarker at different thresholds, did not outperform hscTnT>=14ng/l for detecting MI as shown in table 5. In this comparison it is worth considering that hs-cTnT at 14ng/l is used to aid in the diagnosis itself. At best, H-FABP>=3.8μg/l used to diagnose MI showed no statistical difference to hs-cTnT at 14ng/l (row 3). There were other thresholds tested for H-FABP and some of them are shown in table 5 and none of them exhibit NRI>0 when compared to hs-cTnT at 14ng/l.
Nevertheless, the comparisons of algorithms in table 5 show net gains when a diagnosis of non-MI is made when H-FABP at thresholds of 3.8, 5.3 and 7μg/l are compared to hs-cTnT>=14ng/l (rows 3,4 and 5). However, NRI<0 for those algorithms at presentation since the net gains when non-MI are surpassed by net gains in detecting MI.
Additionally in table 5 there are comparisons for some of the possible combinations of H-FABP and hs-cTnT. There were cases of NRI >0 when compared to hsc l but without statistical significance. It seems that by enforcing the two markers over a threshold (combinations AND instead of OR) it is possible to get NRI>0 with net gains without MI (rows 9 and 10 in table 5). There is still ongoing research in order to stablish how combining H-FABP with hs-cTnT at different thresholds would help to improve on MI detection.
H-FABP is present in high concentrations in the myocardium 30 minutes after an ischemic episode [8] . Additionally, its relative tissue specificity [9] makes it a suitable biomarker to be investigated. Following H-FABP's advantage of early expression ( Figure 1 ) and net gains in non-MI as a sole marker and in combinations with hs-cTnT, we aimed to combine this biomarker with hs-cTnT and ECG anomalies as a rule-out approach, especially under 3 hours of presentation in line with Body et al. [10] . They demonstrated a model of eight variables including hs-cTnT, H-FABP, an indication of ischaemia from ECG and the outcomes of a clinical assessment. In future work we aim to simplify Body's approach using fewer variables and concentrating uniquely in NSTEMIs. Additionally we aim to use the time for onset of symptoms, which is subjective but could be a very important piece of information.
It is important to note the limitation of the study which includes the use of a relatively small dataset.
Conclusions
H-FABP has shown promise among other biomarkers investigated to pair with hs-cTnT according to AUROC and logistic regressions. It does not outperform hs-cTnT for the detection of AMI in the dataset investigated. However, its earlier detection in blood following an ischaemic event, and net gains in classification when a diagnosis of non-MI is made, suggest its use as a rule-out test for suspected AMI patients. If effective, this would allow risk stratification and a more efficient use of resources to the health care system.
